MOG peptide (35-55) amide, a myelin oligodendrocyte glycoprotein (MOG) fragment spanning amino acids 35 to 55, selectively stimulates CD4+ T cell expansion and induces experimental autoimmune encephalomyelitis (EAE) in animal models [1] [2] [3].

The expanded CD4+ T cells predominantly target the immunogenic peptide 35-55 of myelin oligodendrocyte glycoprotein (MOG35-55). In contrast, clonally expanded CD8+ T cells exhibit no response to myelin-derived peptides or proteins [1].

Administration of MOG peptide (35-55) at a concentration of 3 mg/mL (0.1 mL, s.c., single dose) actively induces experimental autoimmune encephalomyelitis (EAE) in mice [2]. Additionally, a single subcutaneous dose of MOG peptide (35-55) at 200 μg results in an increased level of the eosinophil chemoattractant eotaxin-1 in the spinal cord during EAE progression in C57BL/6 mice [3].